Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.

[1]  T. Schall,et al.  Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps. , 1996, The Journal of allergy and clinical immunology.

[2]  E. Jaffee,et al.  Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[3]  O. Scott.  Biologic therapy of cancer. , 1996, British Journal of Cancer.

[4]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[5]  P. Coulie,et al.  A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  F. Marshall,et al.  Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[7]  A. Sette,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.

[8]  M. Sanda,et al.  Gene therapy for human prostate cancer. Translational research in the hormone refractory dunning prostate cancer model , 1995 .

[9]  B. Seliger,et al.  Cellular immune response to human renal‐cell carcinomas: Definition of a common antigen recognized by HLA‐A2‐restricted cytotoxic T‐Lymphocyte (CTL) clones , 1994, International journal of cancer.

[10]  J. Renauld,et al.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.

[11]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[12]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  E. Gilboa,et al.  Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. , 1994, Cancer research.

[14]  E. Jaffee,et al.  Demonstration of a rational strategy for human prostate cancer gene therapy. , 1994, The Journal of urology.

[15]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[16]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[17]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[18]  M. Peters,et al.  Mast cells, neutrophils, and eosinophils in prurigo nodularis. , 1993, Archives of dermatology.

[19]  F. Marshall,et al.  High efficiency gene transfer into primary human tumor explants without cell selection. , 1993, Cancer research.

[20]  R. Mulligan,et al.  The basic science of gene therapy. , 1993, Science.

[21]  G. H. Weiss,et al.  Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. , 1993, Urology.

[22]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[23]  F. Leyva-Cobián,et al.  Eosinophil as antigen‐presenting cell: activation of T cell clones and T cell hybridoma by eosinophils after antigen processing , 1992, European journal of immunology.

[24]  G. Del Prete.  Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. , 1992, Allergy.

[25]  S. Bhardwaj.  New approaches to cancer treatment. , 1991, Comprehensive therapy.

[26]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[27]  P. McCue,et al.  Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[29]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[30]  R. Coffman,et al.  Role of Cytokines and CD4+ T‐Cell Subsets in the Regulation of Parasite Immunity and Disease , 1989, Immunological reviews.

[31]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[32]  Daniel Lucey,et al.  Mature human eosinophils have the capacity to express HLA-DR. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Mulligan,et al.  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  H. Maguire,et al.  Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. , 1986, Cancer research.

[35]  H. Sampson,et al.  Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis. , 1985, The New England journal of medicine.

[36]  M. Hanna,et al.  Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine. , 1984, Cancer research.

[37]  D. Loegering,et al.  Immunobiology of eosinophils. , 1984, Annual review of immunology.

[38]  M. Peters,et al.  Localization of eosinophil granule major basic protein in chronic urticaria. , 1983, The Journal of investigative dermatology.

[39]  J. Sokal.  Measurement of Delayed Skin-Test Responses , 1975 .

[40]  R. Herberman,et al.  Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumour cells. , 1971, Clinical and experimental immunology.